Publications by authors named "L Rodriguez-Fernandez-Freire"
Article Synopsis
- This study examined psoriasis prevalence in Spain from 2018 to 2022, finding a significant increase in cases, particularly among older age groups.
- The estimated prevalence reached 1.9% in 2022, with a total rise of 43.3%, indicating stronger increases in both men and women, with men showing slightly higher rates.
- Results suggest factors like better awareness and diagnostics may contribute to this trend, highlighting the need for more research to understand the causes and inform public health strategies.
Aim: This study aimed to investigate the effects of age, period, and cohort on the incidence of psoriasis in Spain from 1990 through 2019 using the Global Burden of Disease (GBD) database and age-period-cohort (A-P-C) analysis.
Methods: We conducted an ecological trend study to analyze the incidence rates of psoriasis in Spain from 1990 through 2019. Joinpoint Regression Program, Version 5.
A Non-Interventional, Multicenter Study to Characterize the Socio-Demographics, Clinical Characteristics, and Management of Generalized Pustular Psoriasis Patients in Spain: IMPULSE Study.
Dermatology
December 2024
Article Synopsis
- Generalized pustular psoriasis (GPP) is a rare and severe skin condition causing painful pustules and systemic inflammation, with limited treatment options available until the approval of spesolimab in 2022.
- In a study of 56 patients in Spain, the average age of diagnosis was 53.7 years, with many experiencing flares linked to past health issues, including hypertension and plaque psoriasis, and most patients requiring off-label treatments such as corticosteroids.
- The study revealed that common symptoms during GPP flares included pustules (88.5%) and erythema (76.9%); complications occurred in 16.1% of patients, highlighting the significant health burden associated with G
Background And Objective: Psoriasis often precedes the onset of psoriatic arthritis (PsA), so dermatologists often face the challenge of early identifying signs of PsA in patients with psoriasis. Our aim was to validate the Spanish version of the PURE-4 questionnaire as a screening tool for PsA, evaluate its performance in terms of sensitivity, specificity, feasibility, reliability, and build validity.
Methods: This was a cross-sectional, observational, multicenter trial of adult patients with psoriasis.
: Psoriasis, a chronic inflammatory skin disease, affects 2-10% of the population globally. Bimekizumab (BMK), a monoclonal antibody targeting IL-17, is a dual inhibitor of IL17 A and F that has shown efficacy in treating moderate to severe plaque psoriasis. This real-world evidence (RWE) study aims to assess BMK's efficiency and safety in naïve and refractory patients.
View Article and Find Full Text PDF